Emerging therapy

Muse cells

Multilineage-differentiating Stress Enduring cells

A distinct cell type with an unusual property — it appears to home to damaged tissue on its own — and an unusually small amount of clinical evidence, almost none of it in children.

Where it stands, condition by condition

The same therapy can be well supported for one problem and completely untested for another. This is the single most common place families are misled.

What it is

Muse cells are a small subpopulation found within mesenchymal stromal cell preparations, identified in Japan and defined by a surface marker normally associated with pluripotent cells.

Two properties attract attention. They appear able to migrate to injured tissue after intravenous delivery rather than needing to be injected into the target, and in laboratory work they survive stress that kills ordinary cells.

Unlike generic “stem cell” offerings, clinical Muse cell work has largely gone through formal product development, with a defined preparation studied in registered early-phase trials.

How it is meant to work

The proposed mechanism combines homing to damaged tissue, some differentiation into local cell types, and the same anti-inflammatory signalling seen with other cell therapies.

Because the cells are reported to be non-tumourigenic in preclinical work, they have been given without the immune suppression usually required for donor cells — a claim that still needs long-term human confirmation.

What has actually been tested

• Registered early-phase trials have been conducted in adults, in conditions such as stroke, heart attack and amyotrophic lateral sclerosis.
• In paediatrics, the most relevant work is early-phase study in newborns with hypoxic-ischaemic encephalopathy, given alongside standard therapeutic cooling.
• Early-phase means the question is whether the product can be given safely and at what dose. These studies are not designed to show that a child will do better, and they should not be quoted as if they were.
• If a clinic offers Muse cells for cerebral palsy or autism today, it is offering something that has not been tested for that purpose in a controlled study.

What we still do not know

• Whether any clinical benefit exists in children, for any condition.
• Whether products sold as “Muse cells” outside Japan contain the same characterised cell population.
• Optimal timing — early-phase work targets the acute injury window, not children years after an injury.
• Long-term safety across childhood.

Risks and costs

• The same procedural and infusion risks as other cell therapies.
• A specific risk of mislabelling: because the term is scientifically fashionable, it is used commercially for preparations that have never been shown to contain this cell population.
• Cost and travel for a treatment at an early stage of investigation.

Questions to ask before you agree

1. Is the product a characterised Muse cell preparation, and how was that verified?
2. Which registered trial is this, and what phase?
3. What evidence exists for my child's condition, as opposed to adult stroke?

More in this section